Cancer Research

Lungs
#Antibody #Cancer research #Cancer vaccine #IO Biotech #Lung cancer #Merck #Oncology #Phase II trial

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More

#Cancer Research #News

Corporate collaboration
#Cancer #Orano Med #Orbit Discovery #Peptides #Radiopharmaceuticals

Collaboration to discover novel targeted radioligand therapies

Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.   Under… Read More

#Cancer Research #News

Cancer cells
#Bispecific therapeutics #Cancer research #Collaboration #Drug development #Immatics #Moderna #mRNA

Multi-platform collab to develop innovative oncology therapeutics 

Moderna and Immatics have announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high, unmet medical need.   This broad multi-platform collaboration will leverage the scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s… Read More

#Cancer Research #News

Bladder cancer
#Bladder cancer #EMA #Janssen #Marketing approval authorisation #Regulatory #Urothelial carcinoma

Janssen submits EMA filing for bladder cancer treatment 

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3)… Read More

#Cancer Research #News

CAR-T therapy
#Beam Therapeutics #Cancer research #CAR-T #Clinical trial #Leukaemia #Oncology #T cell activation

First base editing therapeutic for T-ALL/T-LL enters trials

The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase I/II clinical study for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL). Read More

#Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Genmab #Oncology #Phase III trial #Seagen

Antibody-drug conjugate extends overall survival in cervical cancer

In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An independent data monitoring committee determined that OS crossed… Read More

#Cancer Research #News

Childhood Cancer Awareness Month
#Cancer research #Childhood cancer #Clinical trials #Oncology #Paediatrics

Five key studies into drugs for childhood cancers

DDW's Diana Spencer highlights five key clinical studies taking a new therapeutic approach to childhood cancers. Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. However, despite the fact that children’s response to adult cancer drugs is often poor,… Read More

#Cancer Research #Exclusive Content

Telomeres on chromosomes
#Cancer research #Cancer Research UK #Institute of Cancer Research #Oncology

Study identifies potential new cancer drug targets

A new study has provided insights into the biological mechanism that supports survival of hard-to-treat cancers. In the new study, led by scientists at The Institute of Cancer Research and published in Nature Communications, researchers identify a new cellular role of a protein called EXD2 nuclease… Read More

#Cancer Research #News

MRI of the brain showing glioblastoma
#Brain cancer #Cancer research #Cancer vaccine #Immunomic Therapeutics #Oncology #Phase I trial

Plasmid DNA vaccine for brain cancer enters Phase I trial

Immunomic Therapeutics has commenced its Phase I clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. ITI-1001 is an investigational plasmid DNA vaccine therapy designed to target the pp65, IE-1 and… Read More

#Cancer Research #News

#Cancer research #Oncology #Partnership #United States

CancerX initiative aims to boost innovation in cancer treatment

The White House Cancer Moonshot initiative has announced a new public-private partnership to boost innovation in the fight against cancer. CancerX will be co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center. It blends DiMe’s expertise in convening cross-disciplinary groups to develop clinical-quality resources… Read More

#Cancer Research #News

Medical laboratory
#Breast cancer #Cancer research #Evgen Pharma #Oncology #Phase I trial

Phase Ib study proves efficacy of SFX-01 coated tablet formation

Evgen Pharma has revealed the final data from its Phase Ib healthy volunteer study using the company’s new enteric coated tablet formation of its lead asset SFX-01. SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. The company has already completed three trials in patients,… Read More

#Cancer Research #News

Breast cancer research
#Breast cancer #Cancer research #Immunotherapy #Oncology

Where are the advances in treatments for triple-negative breast cancer?

Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is one of the main causes of death in women. However, because these cancers are not driven… Read More

#Cancer Research #Exclusive Content

Cancer cell
#Biomarkers #Breast cancer #Cancer research #Genetics / genomics #Oncology #Personalised medicine #The Institute of Cancer Research

Genetic biomarkers could personalise therapy for TNBC

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours… Read More

#Cancer Research #News #Trending News

Tumour microenvironment
#Cancer research #Cancer Research UK #Immunotherapy #Oncology #Phase I trial #Solid tumours #Sosei Heptares

Immunotherapy for solid tumours progresses to human trials

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating… Read More

#Cancer Research #News

Warfarin
#Cancer research #Columbia University #Drug repurposing #Oncology

Warfarin could be repurposed as a potent cancer drug

A new study has shown that blood thinner warfarin could also treat cancer, as it stops tumours from interfering with a self-destruct mechanism that cells initiate when they detect mutations or other abnormalities (ferroptosis). The research by Columbia University researchers was conducted in human cells and… Read More

#Cancer Research #News #Trending News

#AI / data analytics / healthtech / informatics #Cancer research #Genetics / genomics #Interview #Oncology #Sitting Down With

Sitting down with… Neil Dhawan

Listen to this article on the DDW Podcast: Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company’s approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). RA: How is Totus Medicines attempting to target untreatable or undruggable diseases? ND:… Read More

#Cancer Research #Exclusive Content